536 related articles for article (PubMed ID: 8623926)
41. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
42. Role of DNA content analysis and immunohistochemistry in the evaluation of the risk of unfavourable outcome in Wilms' tumours.
Osterheld MC; Caron L; Meagher-Villemure K
Anticancer Res; 2008; 28(2A):751-6. PubMed ID: 18507016
[TBL] [Abstract][Full Text] [Related]
43. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors.
Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L
Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842
[TBL] [Abstract][Full Text] [Related]
44. Effect of hyperthermia 42.5 degrees C/120 min on 3H-thymidine incorporation in different tissue components of Wilms' tumors: an in vitro study.
Willnow U; Dumon K; Godehardt E
Klin Padiatr; 1996; 208(4):145-50. PubMed ID: 8776702
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
47. The nephroblastomatosis complex and its relationship to Wilms' tumor: a clinicopathologic treatise.
Bove KE; McAdams AJ
Perspect Pediatr Pathol; 1976; 3():185-223. PubMed ID: 184429
[TBL] [Abstract][Full Text] [Related]
48. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors.
Carpentieri DF; Nichols K; Chou PM; Matthews M; Pawel B; Huff D
Mod Pathol; 2002 Oct; 15(10):1080-6. PubMed ID: 12379755
[TBL] [Abstract][Full Text] [Related]
49. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
[TBL] [Abstract][Full Text] [Related]
50. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
[TBL] [Abstract][Full Text] [Related]
51. Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution.
Roth J; Blaha I; Bitter-Suermann D; Heitz PU
Am J Pathol; 1988 Dec; 133(3):596-608. PubMed ID: 2849302
[TBL] [Abstract][Full Text] [Related]
52. Functional properties of WT1.
Haber DA; Englert C; Maheswaran S
Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
[TBL] [Abstract][Full Text] [Related]
53. Amplification and expression of EGFR and ERBB2 in Wilms tumor.
Vasei M; Modjtahedi H; Ale-Booyeh O; Mosallaei A; Kajbafzadeh AM; Shahriari M; Ghaderi AA; Soleymanpour H; Kosari F; Moch H; Sauter G
Cancer Genet Cytogenet; 2009 Oct; 194(2):88-95. PubMed ID: 19781441
[TBL] [Abstract][Full Text] [Related]
54. Histopathological variations among cases of Wilms' tumor in Bangladesh and its relationship with prognosis.
Ara T; Khan WA; Ali SM
Bangladesh Med Res Counc Bull; 1997 Aug; 23(2):56-9. PubMed ID: 9465437
[TBL] [Abstract][Full Text] [Related]
55. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
56. Der(16)t(1;16)(q21;q13) in Wilms' tumor: friend or foe.
Mathew P; Douglass EC; Jones D; Valentine M; Valentine V; Rowe S; Shapiro DN
Med Pediatr Oncol; 1996 Jul; 27(1):3-7. PubMed ID: 8614388
[TBL] [Abstract][Full Text] [Related]
57. Analysis of the p53 gene by PCR-SSCP in ten cases of Wilms' tumor.
Defavery R; Lemos JA; Kashima S; Bernardes JE; Scridelli CA; Covas DT; Tone LG
Sao Paulo Med J; 2000 Mar; 118(2):49-52. PubMed ID: 10772697
[TBL] [Abstract][Full Text] [Related]
58. Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.
Tretiakova M; Turkyilmaz M; Grushko T; Kocherginsky M; Rubin C; Teh B; Yang XJ
J Clin Pathol; 2006 Dec; 59(12):1272-7. PubMed ID: 16556665
[TBL] [Abstract][Full Text] [Related]
59. Derivation and characterization of a Wilms' tumour cell line, WiT 49.
Alami J; Williams BR; Yeger H
Int J Cancer; 2003 Nov; 107(3):365-74. PubMed ID: 14506735
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
